Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezurpimtrostat + Atezo/Bev in Unresectable HCC
NCT05448677Phase 2Terminated
- Sponsor
- CHU Grenoble Alpes
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ezurpimtrostat in hepatocellular carcinoma (HCC), sponsored by CHU Grenoble Alpes. Started Dec 2022; status: terminated.
02
Drugs
ezurpimtrostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05448677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448677.